FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562102732> ?p ?o ?g. }

• W2562102732 abstract "Abstract Background: The Inhibitors of Apoptosis (IAP) proteins are a family of molecules that suppress apoptotic cell death. Expression of IAPs is dysregulated in Myelodysplastic Syndrome (MDS) and is a potential path for therapeutic intervention. SMAC (second mitochondrial-derived activator of caspases) is an IAP antagonist, resulting in caspase activation, inhibition of NF-k B and increased apoptosis. Birinapant is a potent bivalent SMAC mimetic under clinical investigation for several cancer types. Pre-clinical data support its investigation in myeloid malignancies, including MDS, and a previous phase 1b study demonstrated promising clinical activity in patients with higher-risk MDS who were naïve or had relapsed or were refractory to prior therapy. In this trial birinapant is combined with 5-azacitidine (5-AZA) in high-risk MDS patients who have not yet been treated with a hypomethylating agent. Methods: This phase 2 ongoing study of birinapant plus 5-AZA in patients with MDS or CMMoL recently completed enrollment to the unblinded portion, in which 9 patients were dosed with birinapant 13 mg/m2 IV twice weekly for 3 weeks of a 28-day cycle plus 5-AZA 75 mg/m2 by IV infusion daily for 7 days of a 28-day cycle. The primary objective of this study is to determine the objective response rate by International Working Group criteria of birinapant plus 5-AZA in patients with high-risk MDS or CMMoL who are naïve to hypomethylating agents. Secondary objectives include assessing the tolerability of this regimen, and determining the pharmacokinetics and exploratory pharmacodynamics of the combination. Results: Of the 9 patients enrolled, 6 patients had high or very high risk MDS; no patients had CMMoL. 8 patients were age ≥60 years. All patients were naïve to 5-AZA. Of the 9 patients enrolled, 6 completed up to four cycles of chemotherapy and were considered evaluable for response; three discontinued therapy prior to Cycle 4 (patient or investigator decision, or occurrence of adverse events (AEs)). Of the 6 evaluable patients, 3 had a complete response (CR), one had a marrow CR, and one had a partial response (PR). A sixth patient had a best response of stable disease at Cycle 4. Of these six patients evaluable, one (PR) was able to proceed to stem cell transplantation. The median duration of response (range) in these patients has not yet been assessed. Adverse events were consistent with the disease under investigation or the known profile of birinapant or 5-AZA. The most common ≥Grade 3 AEs seen in ≥2 patients were neutropenia and thrombocytopenia (5 patients each); fatigue, anemia, increased lipase and syncope (2 patients each). One patient developed a Grade 1 VIth cranial nerve palsy. No serious adverse events were reported in more than one patient, and one fatal event (sepsis) was reported. No patients developed infusion site reaction. Data showing inhibition of NF-k B, a downstream pro-survival molecule activated by IAPs, in circulating blast cells, demonstrated evidence of a potential biomarker in this population. Conclusion: This ongoing phase 2 study provide data for an acceptable safety profile of the combination of birinapant administered with IV 5-AZA. Preliminary evidence of promising clinical activity in this non-randomized, open-label phase was observed. These results provide rationale for the continuation to the next phase of this global randomized, blinded phase 2 study comparing birinapant in combination with 5-AZA vs. 5-AZA alone in patients with high-risk MDS or CMMoL in the front-line setting. Disclosures Ritchie: Celgene: Speakers Bureau; Incyte: Speakers Bureau. Skolnik:TetraLogic Pharmaceuticals: Employment, Equity Ownership." @default.
• W2562102732 created "2017-01-06" @default.
• W2562102732 creator A5016581203 @default.
• W2562102732 creator A5043358427 @default.
• W2562102732 creator A5045006339 @default.
• W2562102732 creator A5067915183 @default.
• W2562102732 creator A5073038475 @default.
• W2562102732 creator A5078887304 @default.
• W2562102732 creator A5080175823 @default.
• W2562102732 date "2015-12-03" @default.
• W2562102732 modified "2023-09-27" @default.
• W2562102732 title "A Phase 2 Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve to 5-Azacitadine: A Preliminary Analysis of Phase 2a" @default.
• W2562102732 doi "https://doi.org/10.1182/blood.v126.23.2904.2904" @default.
• W2562102732 hasPublicationYear "2015" @default.
• W2562102732 type Work @default.
• W2562102732 sameAs 2562102732 @default.
• W2562102732 citedByCount "3" @default.
• W2562102732 countsByYear W25621027322016 @default.
• W2562102732 countsByYear W25621027322020 @default.
• W2562102732 crossrefType "journal-article" @default.
• W2562102732 hasAuthorship W2562102732A5016581203 @default.
• W2562102732 hasAuthorship W2562102732A5043358427 @default.
• W2562102732 hasAuthorship W2562102732A5045006339 @default.
• W2562102732 hasAuthorship W2562102732A5067915183 @default.
• W2562102732 hasAuthorship W2562102732A5073038475 @default.
• W2562102732 hasAuthorship W2562102732A5078887304 @default.
• W2562102732 hasAuthorship W2562102732A5080175823 @default.
• W2562102732 hasConcept C104317684 @default.
• W2562102732 hasConcept C126322002 @default.
• W2562102732 hasConcept C143998085 @default.
• W2562102732 hasConcept C150194340 @default.
• W2562102732 hasConcept C190727270 @default.
• W2562102732 hasConcept C197934379 @default.
• W2562102732 hasConcept C2776239401 @default.
• W2562102732 hasConcept C2776694085 @default.
• W2562102732 hasConcept C2777063308 @default.
• W2562102732 hasConcept C2778375690 @default.
• W2562102732 hasConcept C2778620579 @default.
• W2562102732 hasConcept C2779134260 @default.
• W2562102732 hasConcept C2780007613 @default.
• W2562102732 hasConcept C2780240888 @default.
• W2562102732 hasConcept C2780817109 @default.
• W2562102732 hasConcept C2780976302 @default.
• W2562102732 hasConcept C31760486 @default.
• W2562102732 hasConcept C535046627 @default.
• W2562102732 hasConcept C55493867 @default.
• W2562102732 hasConcept C71924100 @default.
• W2562102732 hasConcept C86803240 @default.
• W2562102732 hasConceptScore W2562102732C104317684 @default.
• W2562102732 hasConceptScore W2562102732C126322002 @default.
• W2562102732 hasConceptScore W2562102732C143998085 @default.
• W2562102732 hasConceptScore W2562102732C150194340 @default.
• W2562102732 hasConceptScore W2562102732C190727270 @default.
• W2562102732 hasConceptScore W2562102732C197934379 @default.
• W2562102732 hasConceptScore W2562102732C2776239401 @default.
• W2562102732 hasConceptScore W2562102732C2776694085 @default.
• W2562102732 hasConceptScore W2562102732C2777063308 @default.
• W2562102732 hasConceptScore W2562102732C2778375690 @default.
• W2562102732 hasConceptScore W2562102732C2778620579 @default.
• W2562102732 hasConceptScore W2562102732C2779134260 @default.
• W2562102732 hasConceptScore W2562102732C2780007613 @default.
• W2562102732 hasConceptScore W2562102732C2780240888 @default.
• W2562102732 hasConceptScore W2562102732C2780817109 @default.
• W2562102732 hasConceptScore W2562102732C2780976302 @default.
• W2562102732 hasConceptScore W2562102732C31760486 @default.
• W2562102732 hasConceptScore W2562102732C535046627 @default.
• W2562102732 hasConceptScore W2562102732C55493867 @default.
• W2562102732 hasConceptScore W2562102732C71924100 @default.
• W2562102732 hasConceptScore W2562102732C86803240 @default.
• W2562102732 hasLocation W25621027321 @default.
• W2562102732 hasOpenAccess W2562102732 @default.
• W2562102732 hasPrimaryLocation W25621027321 @default.
• W2562102732 hasRelatedWork W2178087063 @default.
• W2562102732 hasRelatedWork W2321111455 @default.
• W2562102732 hasRelatedWork W2550013821 @default.
• W2562102732 hasRelatedWork W2552767621 @default.
• W2562102732 hasRelatedWork W2557234452 @default.
• W2562102732 hasRelatedWork W2561654253 @default.
• W2562102732 hasRelatedWork W2563465935 @default.
• W2562102732 hasRelatedWork W2567518952 @default.
• W2562102732 hasRelatedWork W2576334191 @default.
• W2562102732 hasRelatedWork W2579802222 @default.
• W2562102732 hasRelatedWork W2583162692 @default.
• W2562102732 hasRelatedWork W2588409731 @default.
• W2562102732 hasRelatedWork W2589560326 @default.
• W2562102732 hasRelatedWork W2979535942 @default.
• W2562102732 hasRelatedWork W2979743524 @default.
• W2562102732 hasRelatedWork W2980643216 @default.
• W2562102732 hasRelatedWork W2989178613 @default.
• W2562102732 hasRelatedWork W2994190077 @default.
• W2562102732 hasRelatedWork W2994294639 @default.
• W2562102732 hasRelatedWork W3096742444 @default.
• W2562102732 isParatext "false" @default.
• W2562102732 isRetracted "false" @default.
• W2562102732 magId "2562102732" @default.
• W2562102732 workType "article" @default.